SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-07-26
DOI
10.3389/fphar.2018.00828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of clinical severity of cystic fibrosis with variants in the SLC gene family ( SLC6A14 , SLC26A9 , SLC11A1 and SLC9A3 )
- (2017) Stéphanie Villa-Nova Pereira et al. GENE
- Cystic fibrosis gene modifierSLC26A9modulates airway response to CFTR-directed therapeutics
- (2016) Lisa J. Strug et al. HUMAN MOLECULAR GENETICS
- Translating the genetics of cystic fibrosis to personalized medicine
- (2016) Harriet Corvol et al. Translational Research
- Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
- (2016) Jane C Davies et al. Lancet Respiratory Medicine
- Targeting ion channels in cystic fibrosis
- (2015) Marcus A. Mall et al. Journal of Cystic Fibrosis
- Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis
- (2015) Melissa R. Miller et al. JOURNAL OF PEDIATRICS
- Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis
- (2015) Harriet Corvol et al. Nature Communications
- Evidence for a Causal Relationship Between Early Exocrine Pancreatic Disease and Cystic Fibrosis–Related Diabetes: A Mendelian Randomization Study
- (2014) David Soave et al. DIABETES
- Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): Physiological and pathophysiological relevance
- (2014) Elma El Khouri et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
- (2014) Kris De Boeck et al. Journal of Cystic Fibrosis
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)
- (2014) Edward F McKone et al. Lancet Respiratory Medicine
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation
- (2013) Jane C. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Genetic Modifiers of Cystic Fibrosis-Related Diabetes
- (2013) S. M. Blackman et al. DIABETES
- Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities
- (2013) Weili Li et al. HUMAN GENETICS
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
- (2012) Philip H. Quanjer et al. EUROPEAN RESPIRATORY JOURNAL
- Functional analysis of nonsynonymous single nucleotide polymorphisms in human SLC26A9
- (2012) An-Ping Chen et al. HUMAN MUTATION
- Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis
- (2012) Lei Sun et al. NATURE GENETICS
- Differential contribution of SLC26A9 to Cl−conductance in polarized and non-polarized epithelial cells
- (2011) Jiraporn Ousingsawat et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2
- (2011) Fred A Wright et al. NATURE GENETICS
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies
- (2011) Chelsea Taylor et al. PEDIATRIC PULMONOLOGY
- Understanding the population structure of North American patients with cystic fibrosis
- (2010) W Li et al. CLINICAL GENETICS
- SLC26A9 stimulates CFTR expression and function in human bronchial cell lines
- (2010) Martine Avella et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Slc26a9 Is Inhibited by the R-region of the Cystic Fibrosis Transmembrane Conductance Regulator via the STAS Domain
- (2009) Min-Hwang Chang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia
- (2009) Carol A. Bertrand et al. JOURNAL OF GENERAL PHYSIOLOGY
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of SLC26A9, Facilitation of Cl- Transport by Bicarbonate
- (2008) Celine Loriol et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Pharmacogenetic response to albuterol among asthmatics
- (2008) Harriet Corvol et al. PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More